Follow up studies corroborated the loss of Dab2 expression in ovarian and breast cancer and its cell growth suppressive activity, and substantiated the proposal for Dab2 as a tumor suppressor (Mok et al., 1998; Fazili et al., 1999). This evidence concerns the gene DAB2 and breast cancer.